Questions and answers 14May2026.xlsx

This is a Questions and Answers (Q&A) document from a federal contract opportunity for a Portable Patient Transport System (PPTS) prototype development effort. The document addresses clarifications on technical requirements, regulatory compliance, and evaluation criteria from the Statement of Objectives (SOO) and related solicitation documents.

Key technical clarifications include specifications for the PPTS glove port system: 14 total individual glove ports arranged in pairs at specific locations (patient's head, sides near head, sides near torso, and sides near feet) with center-to-center distances between paired ports of 33-43 centimeters; distinction between transfer pouches (for items up to 8" x 12" such as food, water, medication) and pass-through ports (for cabling and medical devices like vent tubes, IV lines, and EKG wires); and confirmation that both intake and exhaust filters must be located outside the containment enclosure. The Q&A confirms that HEPA-equivalent filtration performance of 99.97% or greater at 0.3 microns is required, with NIOSH P-100 certification acceptable alongside other equivalent certifications meeting NIOSH criteria. Additional technical responses address operating temperature ranges referenced in the SOO and associated military standards, and clarify that alternative interface designs achieving equivalent clinical functionality may be considered. Regarding regulatory and compliance matters, the document confirms Berry Amendment compliance is mandatory, requires identification of raw material sources, and states that non-compliant initial deliverables with promises of final compliance do not meet the government's preference—prototype testing should use Berry-compliant designs. Data rights requirements strongly prefer Unlimited Rights for all technical data, software, and intellectual property developed under the effort. FDA marketing authorization and full airworthiness solution briefs are required by end of Phase III, with offerors demonstrating credible approaches to core objectives through draft Interface Control Documents and FDA 510(k) clearance status submissions. Affordability will be considered across all phases of the Other Transaction Agreement.